{
  "id": 16664315,
  "title": "Patients given apalutamide and hormone therapy around surgery may cut their risk of metastasis or death",
  "url": "https://urgent.news/2026/10/26/patients-given-apalutamide-and-hormone-therapy-around-surgery-may-cut",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-26T21:00:06.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-10-patients-apalutamide-hormone-therapy-surgery.html"
  },
  "original_language": "en",
  "account": null,
  "summary": "An international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer with apalutamide—a next-generation neoadjuvant androgen-receptor pathway inhibitor (ARPI)—plus hormone therapy before and after prostate cancer surgery was further validated by a substudy demonstrating a reduced risk of metastasis or death compared with standard of care.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}